While the rate of vitiligo was similar to that observed in a global pooled analysis of patients with melanoma receiving pembrolizumab (12.0%), the number of patients reporting elevated alanine aminotransferase in KEYNOTE-151 was comparably much higher (4.4%) (9). The gene discussed is GPT; the disease is vitiligo.